Connect your AI

Spyre Therapeutics, Inc. SYRE Price / book

Price / book at other companies

Bristol-Myers SquibbBMY

6.2×-1.0×

Eli LillyLLY

26.3×-20.7×

PfizerPFE

1.8×+0.2×

Johnson & JohnsonJNJ

7.3×+2.1×

Merck & Co.MRK

6.5×+1.8×

AbbVieABBV

261×+221×

Other financials

Income statement

Revenue-—

Operating income-$45.6M+14.8%

Net income-$69.0M-54.1%

EPS (diluted)-$0.74-23.3%

Balance sheet

Cash & equivalents$97.2M+100%

Total debt$4.3M-9.6%

Total equity$670.8M+39.0%

Total assets$764.0M+34.1%

Cash flow

Operating cash flow-$57.4M-40.0%

CapEx-—

Free cash flow-$39.4M-26.8%

Valuation

Market cap$7.67B+307%

Profitability

Operating margin-39,428.9%-49,795pp

Net margin-52,939.7%-61,871pp

FCF margin-3,442.8%-3,807pp

Returns & leverage

Return on equity-31.1%-10.7pp

Debt / equity0.1×+0.1×

Current ratio9×+0.9×

Where this comes from

Calculated from Spyre Therapeutics, Inc.’s reported figures.

market cap/total stockholders equity=5.9×

Based on the most recent quarter.

The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Spyre Therapeutics, Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Spyre Therapeutics, Inc.'s price / book?: Spyre Therapeutics, Inc. (SYRE) reported price / book of 5.9× in Q1 2026.
How has Spyre Therapeutics, Inc.'s price / book changed year-over-year?: Spyre Therapeutics, Inc.'s price / book increased by 193.1% year-over-year, from 2× to 5.9×.
What is the long-term trend for Spyre Therapeutics, Inc.'s price / book?: Over 5 years (2020 to 2025), Spyre Therapeutics, Inc.'s price / book has grown at a 3.4% compound annual growth rate (CAGR), from 3× to 3.6×.
What does price / book mean?: Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.